# A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

> **NCT06537505** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beidahuang Industry Group General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Apatinib
- **PROCEDURE:** microwave ablation

## Key facts

- **NCT ID:** NCT06537505
- **Lead sponsor:** Beidahuang Industry Group General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537505, "A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06537505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*